Cargando…
Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Approximately 25-30% of patients with non-small cell lung cancer (NSCLC) present with early stage disease and undergo surgery with curative intent. Despite complete tumor resection, many of these patients will develop systemic relapses with or without local relapses and will eventually die from the...
Autor principal: | Pirker, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Research Institute of Tuberculosis and Lung Disease
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153177/ https://www.ncbi.nlm.nih.gov/pubmed/25191395 |
Ejemplares similares
-
Adjuvant chemotherapy of non-small-cell lung cancer
por: Douillard, J.Y.
Publicado: (2013) -
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
por: Tiefenbacher, Andreas, et al.
Publicado: (2018) -
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011) -
Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011) -
The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)